Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: DHR stock price vs GILD: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at GILD's multiple
Needs GILD P/E.
Implied fair value · at DHR's multiple
Needs DHR P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
DANAHER CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
GILEAD SCIENCES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AGILENT TECHNOLOGIES, INC.
DHR vs A
ILLUMINA, INC.
DHR vs ILMN
JOHNSON & JOHNSON
DHR vs JNJ
ABBOTT LABORATORIES
DHR vs ABT
LOEWS CORP
DHR vs L
BERKSHIRE HATHAWAY INC
DHR vs BRK-B
AbbVie Inc.
DHR vs ABBV
AMGEN INC
DHR vs AMGN
BRISTOL MYERS SQUIBB CO
DHR vs BMY
Merck & Co., Inc.
DHR vs MRK
PFIZER INC
DHR vs PFE
REGENERON PHARMACEUTICALS, INC.
DHR vs REGN
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe DHR deserves a premium for its much stronger balance sheet and you expect its margin gap versus GILD to narrow, then hold or accumulate selectively; otherwise, the current valuation looks stretched because DHR trades at 38.6x P/E versus GILD’s 19.2x while also sitting above GILD-implied valuation range.
On a P/E basis, DHR trades at 38.6x versus GILD at 19.2x, yet the provided implied price of $96.99 versus the current price of $194.98 indicates a 50.3% downside in this relative framework. However, the market is also valuing DHR and GILD similarly on P/S at 5.6x and 5.5x, which suggests the earnings multiple gap is doing most of the work.
Supporting Metrics
